Imolope

Loperamide, the active ingredient in Imolope, is an antidiarrheal presented as a tablet for oral use. It reduces the frequency of watery stools in adults and children with acute or chronic diarrhea.

GNH USA supplies Imolope as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imolope (loperamide) is used to manage diarrheal conditions by slowing intestinal transit.

- Acute nonspecific diarrhea: decreases stool frequency and improves stool consistency. - Chronic diarrhea: provides symptomatic relief by reducing intestinal motility. - Travel‑associated diarrhea: helps control loose stools during short‑term travel episodes.

Loperamide is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Constipation: reduced bowel movements leading to hard stools. - Abdominal cramps: mild to moderate discomfort in the abdomen. - Nausea: feeling of queasiness or urge to vomit. - Dizziness: light‑headed sensation, especially when standing quickly. - Dry mouth: reduced salivation causing throat discomfort. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe constipation or bowel obstruction: risk of impaction requiring medical attention. - Toxic megacolon: rare but life‑threatening dilation of the colon. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: QT interval prolongation leading to irregular heartbeats. - Ileus: paralytic obstruction of the intestine.

Before using Imolope, consider the following safety measures.

- Assess hydration status: ensure adequate fluid intake to prevent dehydration. - Avoid use in bacterial enterocolitis: may worsen infection by retaining toxins. - Do not exceed recommended dose: follow prescriber instructions to limit systemic exposure. - Use with caution in hepatic impairment: metabolism is primarily hepatic. - Store at room temperature: keep in the original pack, protect from moisture.

Loperamide can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase loperamide plasma levels. - P‑gp inhibitors (e.g., quinidine): can raise systemic exposure and risk of toxicity. - Opioid agonists: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticholinergics: may enhance constipation. - Other antidiarrheals (e.g., bismuth subsalicylate): may reduce overall efficacy.